FXN and juvenile Huntington disease: But it was also shown to rescue frataxin-induced glial degeneration (Edenharter et al., 2018), alleviate ROS-mediated rhabdomere degeneration in Huntington’s disease models (Campesan et al., 2023), reduce pink/parkin-induced ER stress in a fly Parkinson model (Celardo et al., 2016; but see Basso et al., 2018) and increase lifespan and locomotor activity (Rana et al., 2017; Tapia et al., 2021).